Calithera Biosciences, Inc.
CALA evidence brief
What we can confirm
- BioSniper Score:
- 6.0 / 10
- Market Cap:
- $1K
- Lead Asset:
- INCB001158 (Phase 1)
What it means
What to watch
Prepared research question
What matters most for CALA—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper Score
Based on 2 of 6 signals
Limited data coverage
Tracking 3 pipeline candidates · 4 clinical trials for Calithera Biosciences, Inc..
Run Calithera Biosciences, Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Calithera Biosciences, Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Score breakdownBased on 2 of 6 signals · derived from public data
Cash runway data unavailable
Financial health data unavailable
Lead: Phase 2
3 candidates
No upcoming catalysts tracked
No insider transactions in the last 180 days
Pipeline
Regulatory
Financials
Short Interest
as of May 20, 2026- % of float
- 8.9%
- Days to cover
- 0.8
- Shares short
- 417,277
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
CALA short interestFrequently asked questions
What is Calithera Biosciences, Inc.'s lead drug candidate?
Calithera Biosciences, Inc.'s most advanced tracked candidate is INCB001158 (Phase 1) for Oncology and hematology indications.
Who is the CEO of Calithera Biosciences, Inc.?
Chief Executive Officer is the chief executive officer of Calithera Biosciences, Inc. (CALA).
Where is Calithera Biosciences, Inc. headquartered?
Calithera Biosciences, Inc. (CALA) is headquartered in South San Francisco, CA, United States.
What therapeutic areas does Calithera Biosciences, Inc. focus on?
Calithera Biosciences, Inc. develops therapies across Oncology, Rare Disease, Immunology, Respiratory.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.